^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ALK fusion

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
Related tests:
1d
TTC7A-ALK, a novel ALK fusion variant identified in a patient with metastatic lung adenocarcinoma, exhibits excellent response to crizotinib. (PubMed, Transl Oncol)
The patient demonstrated a significant clinical benefit from sequential treatment with crizotinib and alectinib, highlighting TTC7A-ALK as a novel therapeutic target for ALK inhibitors. These findings extend the spectrum of actionable ALK fusions and promote the inclusion of rare fusion detection in clinical diagnostic processes and treatment strategies.
Journal
|
EML4 (EMAP Like 4)
|
ALK rearrangement • ALK fusion
|
Xalkori (crizotinib) • Alecensa (alectinib)
5d
GAIN/iCat2: The ICat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study (clinicaltrials.gov)
P=N/A, N=825, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Jan 2024 --> Jan 2026
Trial completion date • Trial primary completion date
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
ALK fusion • NTRK fusion
6d
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. (clinicaltrials.gov)
P2, N=120, Recruiting, Hunan Province Tumor Hospital | Phase classification: P1 --> P2
Phase classification
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion
|
PD-L1 IHC 22C3 pharmDx
|
Lenvima (lenvatinib) • reozalimab (IBI318)
6d
SplitFusion enables ultrasensitive gene fusion detection and reveals fusion variant-associated tumor heterogeneity. (PubMed, Patterns (N Y))
Using data from 515 The Cancer Genome Atlas (TCGA) samples, SplitFusion showed the highest sensitivity and uncovered two cases of SLC34A2::ROS1 that were missed in previous studies. These capabilities make SplitFusion highly suitable for clinical applications and the study of fusion-defined tumor heterogeneity.
Journal
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4) • AR (Androgen receptor) • SLC34A2 (Solute carrier family 34 member 2) • DUX4 (Double Homeobox 4)
|
ALK fusion • AR splice variant 7
7d
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience. (PubMed, J Liq Biopsy)
This is the first investigation to explore the impact of circulating anti-ALK a-abs on BM. Prospective studies with longer follow-up are warranted to further explore the impact of anti-ALK a-abs on BM.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK rearrangement • ALK fusion
7d
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers. (PubMed, J Liq Biopsy)
ctDNA testing to detect oncogenic fusions or METexon14 mutations in advanced NSCLC patients is useful, even if type of gene alterations and clinical characteristics could influence the driver detection rate. Liquid biopsy represents a complementary tool to tissue genotyping, however more sensitive approaches for gene fusions and METexon14 detection are needed to implement its strength and reliability.
Journal • Liquid biopsy • Next-generation sequencing
|
KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SMAD4 (SMAD family member 4)
|
TP53 mutation • KRAS mutation • NRAS mutation • ALK positive • RET fusion • ALK rearrangement • ALK fusion • ALK mutation • ROS1 fusion • ROS1 positive • ROS1 rearrangement • RET positive
|
AVENIO ctDNA Expanded Kit
9d
Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies. (PubMed, Lung Cancer)
This study demonstrates marked improvements in survival for patients with Stage IV NSCLC, particularly in the last six years, despite the increase in brain metastases and elderly patients. This finding suggests the crucial role of novel therapies in enhancing survival outcomes.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK fusion
11d
SKB264-Ⅱ-08: SKB264 Monotherapy in Selected Subjects with Advanced Solid Tumors (clinicaltrials.gov)
P2, N=321, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2024 --> Dec 2025
Enrollment closed • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • EGFR wild-type • ALK fusion
|
docetaxel • sacituzumab tirumotecan (MK-2870)
17d
Identification of Oncogenic Alterations in 124 Cases of Pediatric Papillary Thyroid Carcinoma: BEND7::ALK, DLG5::RET, and CCDC30::ROS1 Fusions Induce MAPK Pathway Activation. (PubMed, Endocr Pathol)
Our data highlights the genetic landscape of Chinese PPTC patients, with RTK fusions being associated with aggressive clinicopathologic features. The rare fusions BEND7::ALK, DLG5::RET, and CCDC30::ROS1 may contribute to PPTC development with a BRAF-like effect.
Journal
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TERT (Telomerase Reverse Transcriptase) • DICER1 (Dicer 1 Ribonuclease III)
|
BRAF V600E • BRAF V600 • ALK fusion • ROS1 fusion
19d
Lorlatinib for Newly-Diagnosed High-Grade Glioma with ROS or ALK Fusion (clinicaltrials.gov)
P1, N=15, Not yet recruiting, Nationwide Children's Hospital | Trial completion date: Sep 2034 --> Jun 2035 | Initiation date: Sep 2024 --> Jun 2025 | Trial primary completion date: Sep 2027 --> Jun 2028
Trial completion date • Trial initiation date • Trial primary completion date
|
ALK fusion • ROS1 fusion
|
carboplatin • Lorbrena (lorlatinib) • cyclophosphamide
19d
PLCXD3-ALK, a novel ALK rearrangement in lung squamous cell carcinoma and its clinical responses to ALK inhibitors. (PubMed, J Thorac Dis)
The activation of downstream pathways and the response to ALK inhibitors crizotinib and alectinib were demonstrated by western blotting (WB). We identified and functionally validated PLCXD3-ALK as a novel rare fusion in NSCLC that has not been previously reported. It can serve as a meaningful therapeutic target for ALK inhibitors of ALK + NSCLC.
Journal
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
|
ALK positive • ALK rearrangement • ALK fusion • ALK mutation
|
Xalkori (crizotinib) • Alecensa (alectinib)
20d
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) (clinicaltrials.gov)
P1, N=65, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial primary completion date: Dec 2024 --> Dec 2025
Trial primary completion date
|
ALK fusion • ALK mutation • ALK translocation
|
Lorbrena (lorlatinib) • cyclophosphamide • topotecan • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
21d
Research Progress of ALK Activation Pattern Changes and Targeted Therapy in Advanced Lung Cancer (PubMed, Zhongguo Fei Ai Za Zhi)
However, the effect of different types of gene changes in molecular targeted therapy is different. Therefore, this paper introduced the relevant contents of different variants of ALK gene, focused on the research progress of targeted therapy, and proposed the future development direction..
Review • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement • ALK fusion
21d
Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report (PubMed, Zhongguo Fei Ai Za Zhi)
The patient developed resistance to Lorlatinib treatment accompanied by mesenchymal-epithelial transition factor (MET) amplification. Effective tumor control was achieved with the combined use of Crizotinib and Lorlatinib, providing a valuable reference for further exploration of treatment strategies following resistance to ALK-TKIs in clinical practice..
Journal
|
ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4)
|
ALK positive • MET amplification • ALK fusion
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
27d
PLATFORM Study of Precision Medicine for Rare Tumors (clinicaltrials.gov)
P2, N=770, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting | Trial completion date: Jul 2023 --> Jul 2028 | Trial primary completion date: Jul 2022 --> Jul 2026
Enrollment open • Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion
|
Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)
28d
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
ALK fusion • EGFR negative
|
AiRuiKa (camrelizumab) • pemetrexed
1m
Genomic landscaping of receptor tyrosine kinase ALK with highly frequent rearrangements in cancers. (PubMed, IUBMB Life)
The structural instability of ALK and partner genes, coupled with the inherent variability of breakpoint sequences, leads to the formation of potent kinase-activated oncogenes, which play a critical role in tumorigenesis. While the occurrence of ALK fusions with partner genes is random, specific combinations lead to the generation of oncogenes.
Journal
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • NPM1 (Nucleophosmin 1)
|
ALK fusion
1m
BRCA1-Associated Protein-1 Inactivated Melanoma Arising in a Pre-existing Nevus With ALK Fusion and Low Tumor Mutational Burden. (PubMed, Am J Dermatopathol)
The tumor was completely excised with negative margins. The patient is doing well at 17 months follow-up with no signs of recurrence.
Journal • Tumor mutational burden • BRCA Biomarker
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • BAP1 (BRCA1 Associated Protein 1) • VHL (von Hippel-Lindau tumor suppressor) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • PRAME (Preferentially Expressed Antigen In Melanoma) • MAP2K7 (Mitogen-Activated Protein Kinase Kinase 7) • RREB1 (Ras Responsive Element Binding Protein 1)
|
TP53 mutation • BRAF V600E • BRAF V600 • ALK positive • TMB-L • ALK fusion • ALK mutation
1m
Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report. (PubMed, Front Oncol)
In addition to reporting the identification of a novel ALK fusion, XPO1-ALK (intergenic), and the sensitivity and safety of brigatinib treatment for lung cancer, this study increased the list of known ALK fusion partners in ALK-positive NSCLC. This case report has a significant clinical reference.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK rearrangement • ALK fusion
|
Alunbrig (brigatinib)
1m
Review • Journal • IO biomarker
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
|
ALK positive • ALK rearrangement • ALK fusion
1m
Long-term survival of an ALK fusion lung adenocarcinoma patient with high mutation burden and microsatellite instability high: a case report. (PubMed, Anticancer Drugs)
The patient experienced progression on initial iruplinalkib and subsequent alectinib therapy within 5 months. After the failure of third-line therapy with cisplatin-pemetrexed combined with bevacizumab, she received sintilimab plus anlotinib which led to a progression-free survival of 6.5 months. She received sintilimab combined with albumin-paclitaxel plus carboplatin and achieved partial response after 6 months...After progression on ICB-based therapy, the patient was treated with lorlatinib and still under follow-up with overall survival of more than 3 years. Our findings highlight the therapeutic potential of ICB-based regimens in patients with MSI-H and ALK-rearranged NSCLC.
Journal • Tumor mutational burden • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • EML4 (EMAP Like 4) • STK11 (Serine/threonine kinase 11) • MLH1 (MutL homolog 1)
|
PD-L1 expression • TP53 mutation • TMB-H • MSI-H/dMMR • ALK positive • ALK rearrangement • STK11 mutation • ALK fusion
|
Avastin (bevacizumab) • cisplatin • carboplatin • Focus V (anlotinib) • Tyvyt (sintilimab) • Alecensa (alectinib) • Lorbrena (lorlatinib) • albumin-bound paclitaxel • pemetrexed • Qi Xinke (iruplinalkib)
1m
Treating Patients With Melanoma and ALK Alterations With Ensartinib (clinicaltrials.gov)
P2, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
|
BRAF V600 • ALK fusion • ALK mutation
|
Ensacove (ensartinib)
1m
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma. (PubMed, Jpn J Clin Oncol)
Currently, olaparib is available for maintenance therapy of BRCA1/2 mutation-positive PDAC. Further therapeutic developments are ongoing for genetic abnormalities involving BRAF V600E and the fusion genes RET, NTRK, NRG, ALK, FGFR2, and ROS1. Overcoming advanced PDAC remains a formidable challenge; however, this review outlines the latest therapeutic strategies that are expected to lead to significant advancements.
Journal • Tumor mutational burden • BRCA Biomarker • MSi-H Biomarker • PARP Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HRD (Homologous Recombination Deficiency) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • KRAS mutation • TMB-H • MSI-H/dMMR • KRAS G12C • BRAF V600 • KRAS G12D • FGFR2 mutation • KRAS wild-type • FGFR2 fusion • ALK fusion • RAS wild-type • KRAS G12
|
Lynparza (olaparib)
1m
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer. (PubMed, Trends Cancer)
This evolution in clinical practice provides a lens through which to review the lessons learned from drug development in oncogene-addicted lung cancers, guided by translational insights into tumor biology and mechanisms of therapeutic resistance. For oncogenic drivers that are less sensitive to single-agent targeted therapies, rationally designed combination strategies will be needed to enable first-line use of targeted agents.
Review • Journal
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK fusion • ROS1 fusion
1m
GO42286: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors (clinicaltrials.gov)
P1/2, N=42, Recruiting, Hoffmann-La Roche | Trial completion date: Jun 2033 --> Feb 2032 | Trial primary completion date: Jun 2033 --> Feb 2028
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK fusion
|
FoundationOne® CDx
|
Alecensa (alectinib)
1m
Identification of the molecular characterization and tumor microenvironment of thoracic inflammatory myofibroblastic tumors. (PubMed, J Formos Med Assoc)
Patients with thoracic IMT patients are typically young with early-stage disease. ALK fusion were the most common genetic alteration, particularly in spindle-cell patterns. Characterization of the tumor microenvironment indicates the potential of immune profiling in the tumor biology and targeted immunotherapy approaches.
Journal • IO biomarker
|
ALK (Anaplastic lymphoma kinase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • TPM3 (Tropomyosin 3) • DCTN1 (Dynactin Subunit 1)
|
ALK fusion
1m
Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy. (PubMed, JCEM Case Rep)
The mechanistic target of rapamycin (mTOR) inhibitor everolimus could not be obtained due to lack of insurance coverage, so the patient was treated with single-agent pembrolizumab. The patient was then followed at an outside institution and was transitioned to hospice at time of progression per his preference. He died 4 years after his initial diagnosis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
ALK (Anaplastic lymphoma kinase)
|
ALK fusion
|
Keytruda (pembrolizumab) • everolimus • sirolimus
2ms
IM-BATTLE-2 Program: Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced (clinicaltrials.gov)
P1/2, N=37, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
KRAS mutation • EGFR T790M • ALK fusion
|
Keytruda (pembrolizumab) • Mekinist (trametinib)
2ms
Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer. (PubMed, Thorac Cancer)
EML4-ALK short variants and TP53 mutations are both adverse factors for first-line alectinib efficacy, but they have little effect on first-line crizotinib.
Retrospective data • Journal
|
TP53 (Tumor protein P53) • EML4 (EMAP Like 4)
|
TP53 mutation • TP53 wild-type • ALK fusion • ALK mutation
|
Xalkori (crizotinib) • Alecensa (alectinib)
2ms
A rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring a STRN-ALK fusion by artificial intelligence and molecular modelling: a case report. (PubMed, Transl Lung Cancer Res)
Our model calculations suggested that the effect of the translocation was to induce the dimerization of ALK into a complex that distorted the binding pocket, which is the same for alectinib, lorlatinib and crizotinib. Our observations suggest that molecular modelling based on artificial intelligence (AI) tools may offer potential predictive information in fusions with rare partner genes. Further retrospective and prospective studies are warranted to demonstrate the predictive robustness of these tools.
Journal
|
ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
|
ALK fusion • ALK translocation
|
Xalkori (crizotinib) • Alecensa (alectinib) • Lorbrena (lorlatinib)
2ms
Successful long-term outcome of neoadjuvant sequential targeted therapy and chemotherapy for stage III non-small cell lung carcinoma: 10 case series. (PubMed, Transl Lung Cancer Res)
The main adverse events of TKIs were grade 3 liver damage and grade 3 skin rash, which required a change in the drug from gefitinib to afatinib and dose reduction, respectively. Successful long-term outcomes were achieved after sequential targeted therapy and chemotherapy, followed by surgery for stage III NSCLC. However, it is noteworthy that postoperative treatment may have also contributed to minimizing postoperative recurrence.
Journal
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK fusion
|
Gilotrif (afatinib) • gefitinib
2ms
Characteristics of the immune microenvironment and their clinical significance in lung adenocarcinoma patients with different ALK fusion variants. (PubMed, Transl Lung Cancer Res)
LUAD patients with short ALK fusion variant-driven tumors exhibited worse prognosis than those with long ALK fusion variant-driven tumors. The tumor immune microenvironments are heterogeneous across different ALK fusion variants with short variants characterized by higher levels of TIL, especially NK cells, but by less TLS development than long variants ALK+ LUAD, which disfavor disease outcomes.
Journal • IO biomarker
|
ALK (Anaplastic lymphoma kinase) • LAG3 (Lymphocyte Activating 3)
|
ALK rearrangement • ALK fusion • LAG3 expression
2ms
Evaluate the Efficacy and Safety of Ensartinib Combined with Radiotherapy in ALK-Rearranged Non-Small Cell Lung Cancer Patients with Brain Metastases: A Prospective, Multi-center, Single-arm, Phase II Trial (ChiCTR2400093994)
P2, N=20, Recruiting, The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University
New P2 trial
|
ALK positive • ALK fusion • ALK mutation
|
Avastin (bevacizumab) • Ensacove (ensartinib)
2ms
New P2 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
ALK fusion
|
docetaxel • Loqtorzi (toripalimab-tpzi) • tifcemalimab (TAB004)
2ms
Trial completion date
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET rearrangement
|
Rybrevant (amivantamab-vmjw) • amivantamab SC (Ami-LC)
2ms
Renal cell carcinoma with ALK-TPM3 gene fusion and ALK amplification: A case report and literature review. (PubMed, Pathol Res Pract)
We report the first case of ALK-RCC with concurrent ALK amplification and fusion. This article presents the clinical data, morphology, immunohistochemistry, and molecular characteristics of this case, with the aim of enhancing the clinical and pathological understanding of ALK-RCC among clinicians and pathologists.
Journal
|
ALK (Anaplastic lymphoma kinase) • TPM3 (Tropomyosin 3) • CA9 (Carbonic anhydrase 9) • PAX8 (Paired box 8)
|
ALK rearrangement • ALK fusion • ALK amplification
2ms
Assessment of Exhaled Breath Condensate for ALK, RET, ROS1, and NTRK1 Fusion Transcript Detection in NSCLC: Comparison With Tissue and Liquid Biopsy Samples. (PubMed, Thorac Cancer)
In conclusion, EBC samples provide a valuable, noninvasive medium for detecting clinically relevant and previously uncharacterized fusion transcripts in non-small cell lung cancer (NSCLC). The high concordance between EBC and tissue biopsies suggests that EBC could complement tissue biopsy for effective diagnosis and monitoring of NSCLC. These findings underscore the importance of comprehensive molecular profiling using multiple sample types to enhance diagnostic precision and optimize therapeutic outcomes in lung cancer management.
Clinical • Journal • Liquid biopsy
|
ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • KIF5B (Kinesin Family Member 5B) • SQSTM1 (Sequestosome 1)
|
NTRK1 fusion • RET fusion • ALK fusion • KIF5B-RET fusion • ROS1 fusion
2ms
Enrollment closed • Tumor mutational burden
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion • KRAS G12
|
FoundationOne® CDx
|
Lumakras (sotorasib)
2ms
Occult collision tumor of the gastroesophageal junction comprising adenocarcinomas with distinct molecular profiles. (PubMed, Cancer Genet)
This case illustrates one way in which NGS can reveal diagnoses such as collision tumor that are wholly unexpected based on clinical and histological grounds. Such diagnoses can have important implications for patient care, particularly in cases where there is discordance for targetable molecular alterations.
Journal
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2)
|
MSI-H/dMMR • ALK fusion
2ms
Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report (PubMed, Zhongguo Fei Ai Za Zhi)
This report describes a case of a locally advanced NSCLC patient with dual driver gene mutations (EGFR L858R combined with primary METamp), the tumor did not shrink after 1 month of Gefitinib monotherapy, but significantly subsided after 4 months of Savolitinib monotherapy. After radical surgery, the pathological results proved pathological complete response (pCR) of the tumor, and the patient had a good response to postoperative continual Savolitinib treatment, with no recurrence nor metastasis observed to date. This case reports the feasibility and effectiveness of neoadjuvant targeted therapy for locally advanced NSCLC with primary METamp, aiming to provide effective reference for perioperative treatment of locally advanced NSCLC with primary METamp..
Journal
|
ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • MET amplification • MET exon 14 mutation • ALK fusion
|
gefitinib • Orpathys (savolitinib)
2ms
Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer (PubMed, Zhongguo Fei Ai Za Zhi)
In recent years, there are increasing clinical evidences suggesting that the combination of ALK inhibitors with surgical treatment holds significant potential for clinical application in resectable early and locally advanced non-small cell lung cancer (NSCLC) patients. This review aims to summarize the advances in neoadjuvant targeted therapy for ALK fusion positive NSCLC and discuss its advantages and challenges in clinical practice..
Review • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK fusion • ALK mutation
2ms
RET-AREAL: a multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs. (PubMed, Cancer Lett)
Notably, patients with c-RET had a better prognosis than those with s-RET (median TTF: NR versus 5.67 months, P=0.037, median OS: NR versus 9.83 months, P=0.047). In conclusion, pralsetinib-based therapy may be a potential strategy to overcome acquired RET fusion after resistance to EGFR/ALK-TKIs.
Journal • Real-world evidence
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B) • CCDC6 (Coiled-Coil Domain Containing 6)
|
EGFR mutation • EGFR exon 19 deletion • RET fusion • ALK fusion • RET mutation • KIF5B-RET fusion
|
Gavreto (pralsetinib)